<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346017</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-IL6-COVID-19</org_study_id>
    <nct_id>NCT04346017</nct_id>
  </id_info>
  <brief_title>Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome</brief_title>
  <official_title>Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francis Corazza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring&#xD;
      hospitalization in intensive care seems related to deregulation of cytokines with very high&#xD;
      levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. In order to elucidate the mechanism of this&#xD;
      hyper inflammatory syndrome we will measure a panel of pro and anti inflammatory cytokines,&#xD;
      as well as known markers of macrophage activation syndrome.&#xD;
&#xD;
      To determine the role of activation of the complement cascade the most important complement&#xD;
      factors and their activation markers will be measured.&#xD;
&#xD;
      The changes of those parameters will be monitored after administration of an anti-IL6R&#xD;
      antibody therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with severely progressive SARS-Cov-2 Coronavirus infection, the elderly and&#xD;
      immunocompromised are at greater risk of progressing to a serious image of ARDS (Acute&#xD;
      Respiratory Distress syndrome). A recent study has shown that patients, sometimes young,&#xD;
      requiring hospitalization in intensive care have deregulation of cytokines with very high&#xD;
      levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. The cytokines involved in the pathogenesis and&#xD;
      clinical manifestations of CRS are mainly IL-6, gamma interferon (IFN-g), tumor necrosis&#xD;
      factor alpha (TNF-a) and IL-10.&#xD;
&#xD;
      Although immunoinflammatory therapy is not systematically recommended in pneumonia linked to&#xD;
      SARS-CoV-2, given the CRS and the pathophysiological results of pulmonary edema and the&#xD;
      formation of the hyaline membrane, a targeted therapeutic approach and temporally accompanied&#xD;
      by adequate ventilatory support could be beneficial in patients with severe pneumonia who&#xD;
      develop ARDS. Tocilizumab (Roactemra®) is a drug that blocks the IL-6 receptor commonly&#xD;
      prescribed for the treatment of rheumatoid arthritis. The intravenous formulation has been&#xD;
      approved for the treatment of CRS which occurs during treatment with Car-T; given the&#xD;
      clinical picture and cytokine levels in patients with severe SARS-Cov-2 pneumonia,&#xD;
      Tocilizumab or another anti-IL6R antagonist may reasonably be expected to contribute to the&#xD;
      control of virus-induced Systemic Inflammatory Response Syndrome (SIRS) in patients with&#xD;
      elevated levels of IL-6.&#xD;
&#xD;
      The objectivation of high interleukin 6 levels in these patients should be an important&#xD;
      scientific argument to justify the administration of therapy based on antagonization of IL6.&#xD;
      Measurement of other pro inflammatory cytokines will shed light on the mechanism of the&#xD;
      inflammatory syndrome induced by the SARS-CoV-2 virus.&#xD;
&#xD;
      One of the pathophysiological mechanisms of pulmonary pathology could be the induction of the&#xD;
      production of complement factors by interleukin 6 as well as the activation of the complement&#xD;
      cascade by the virus via the lectin pathway. It is known that one of the effects of&#xD;
      Tocilizumab is to reduce the concentration of the various complement factors, the synthesis&#xD;
      of which is under the control of interleukin 6. This is why this study proposes to measure&#xD;
      certain parameters of the complement (CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2) in order&#xD;
      to objectify and quantify this activation.&#xD;
&#xD;
      If the activation of the complement proves significant it could be an argument for a&#xD;
      treatment targeting more specifically the cascade of the complement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL6 concentration</measure>
    <time_frame>Before anti-IL6R treatment (baseline)</time_frame>
    <description>Interleukine 6, soluble IL6-R, complex IL6-IL6R concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL6 concentration change from baseline value</measure>
    <time_frame>Twice a week from day 1 to day 14 post anti-IL6R administration</time_frame>
    <description>Interleukine 6 soluble IL6-R, complex IL6-IL6R variation compared to baseline value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complement parameters</measure>
    <time_frame>Before anti-IL6R treatment (baseline)</time_frame>
    <description>CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complement parameters change from baseline values</measure>
    <time_frame>Twice a week from day 1 to day 14 post anti-IL6R administration</time_frame>
    <description>CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2 variation compared to baseline values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory cytokines baseline concentrations</measure>
    <time_frame>Before anti-IL6R treatment (baseline)</time_frame>
    <description>Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory cytokines change from baseline values</measure>
    <time_frame>Twice a week from day 1 to day 14 post anti-IL6R administration</time_frame>
    <description>Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18 variation compared to baseline values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of markers of macrophage activation</measure>
    <time_frame>Before anti-IL6R treatment (baseline)</time_frame>
    <description>sCD25, sCD163, sCD14, glycosylated ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of macrophage activation change from baseline values</measure>
    <time_frame>Twice a week from day 1 to day 14 post anti-IL6R administration</time_frame>
    <description>sCD25, sCD163, sCD14, glycosylated ferritin variation compared to baseline values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ventilation support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will include Covid-19 infected patients with non-invasive or invasive ventilation support (BCRSS score ≥3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group will include Covid-19 infected patients who don't have respiratory problems justifying a transfer to intensive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cytokines dosage</intervention_name>
    <description>Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Ventilation support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Complement dosage</intervention_name>
    <description>Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Ventilation support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  End of the initial phase of high viral load of SARS-Cov-2 (for example apyretic&gt; 72h&#xD;
             and / or at least 7 days after the onset of symptoms)&#xD;
&#xD;
          -  Worsening of respiratory exchanges which require non-invasive or invasive ventilation&#xD;
             support (BCRSS score ≥3)&#xD;
&#xD;
          -  High levels of IL-6 (&gt; 40 pg / ml); alternatively high levels of d-dimer and / or PCR&#xD;
             and / or ferritin and / or fibrinogen gradually increase.&#xD;
&#xD;
          -  A control group will be formed by patients in the Covid unit who do not have&#xD;
             respiratory problems justifying a transfer to intensive care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented sepsis caused by other pathogens other than SARS-Corv-2.&#xD;
&#xD;
          -  Presence of comorbidities likely to lead, according to clinical judgment, to an&#xD;
             unfavorable result&#xD;
&#xD;
          -  Immunosuppressive anti-rejection therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francis Corazza, MD</last_name>
    <phone>024772506</phone>
    <email>francis.corazza@chu-brugmann.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Corazza, MD</last_name>
      <phone>32 2 477 25 06</phone>
      <email>francis.corazza@chu-brugmann.be</email>
    </contact>
    <contact_backup>
      <last_name>Carole Nagant, PhD</last_name>
      <phone>32 2 477 25 07</phone>
      <email>carole.nagant@lhub-ulb.be</email>
    </contact_backup>
    <investigator>
      <last_name>Carole Nagant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Stordeur, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Francis Corazza</investigator_full_name>
    <investigator_title>Head of the Immunology Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement System Proteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

